We believe that these data reveal critical insights on the potential benefit of VYKAT XR to important subpopulations of individuals living with PWS,” said Dr. Anish Bhatnagar, Chief Executive Officer ...

Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety ...

The grant was awarded through the NIH Helping to End Addiction Long-term ® Initiative, a trans-agency effort aimed at speeding solutions to the opioid overdose crisis, accelerating the development of ...

The Phase 1/2a trial is a two-part, single-arm, prospective study aimed at determining the maximum tolerated dose (MTD), safety, and tolerability of REYOBIQ in pediatric patients aged 6 to 21 years ...

End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer’s Disease Scheduled - - Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies - PURCHASE, N.Y., June 25, 2025 ...

Dr. Weikang Tao, the global R&D head of Qilu Pharmaceutical commented: “We greatly appreciate the collaboration, efforts and support of both Arbutus and Qilu's project teams for the development of ...

“I turn 65 this fall and have told my fellow Directors that I would like to retire from full-time work by early 2026,” said Michael F. Brigham, President and CEO. “I originally joined ImmuCell in 1989 ...

ProtoBind-Diff was developed as a foundational component of Gero’s generative drug discovery platform. The model leverages pre-trained protein embeddings (ESM-2) and a denoising diffusion framework to ...

Verano will host a grand re-opening weekend-long Summer Festival celebration at Zen Leaf Cave Creek featuring giveaways, local artisan pop-ups, food trucks, and meet-and-greets with rap icons Dizzy ...

About Endlink Endlink is a healthcare technology company accelerating digital transformation for payers and providers. With a focus on interoperability, clinical intelligence, and workflow automation, ...

SUNNYVALE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...

The first patient was enrolled at Yale School of Medicine’s Department of Psychiatry, marking a significant milestone in the trial.